Market news, stock analysis and investing ideas

Neuropace Sinks After Guidance Cut and Three Downgrades: What It Means for NPCE

Neuropace closed Friday 37.1% below Thursday's close after cutting its 2026 revenue outlook and missing third-quarter revenue estimates. Wells Fargo, JPMorgan and Leerink downgraded the stock, and volume ran about 52 times the 10-day average.

Neuropace Sinks After Guidance Cut and Three Downgrades

Neuropace, Inc. (NASDAQ: NPCE) closed Friday, Nov. 13, at $7.56, down 37.1% from Thursday's close, after it cut its 2026 revenue guidance (the company's own forecast) in an 8-K filed at 4:07 p.m. ET Thursday, after the close. The epilepsy device maker now expects $91 million to $92 million, down from $99.5 million to $101.5 million, and reported third-quarter revenue of $23.1 million.

A guidance cut that took more than a third off the stock

Neuropace lost 37.1% from Thursday's close on a revenue miss and a lower 2026 forecast, though shares recovered part of an early 48% drop. Wells Fargo, JPMorgan and Leerink Partners downgraded the stock on Friday. Management attributes the shortfall to a few large accounts and to changes in its field organization.

Shares gapped down 48% in pre-market, then regained part of the loss

Thursday's regular session was not the problem: the stock fell 3.99% to $12.02 before the report. In after-hours trading (the session after the 4:00 p.m. close), it dropped 33.61%, hours before the downgrades arrived Friday morning.

In Friday's pre-market session (trading before the 9:30 a.m. open), shares changed hands at $6.25, 48% below Thursday's close, in a range of $6.14 to $8.40. Only 110,696 shares traded, fewer than the 10-day average of 149,551 for a full day.

The regular session was far busier. Volume reached 5.79 million shares, about 52 times the 10-day average and equal to 21.5% of the 26.85 million shares in the float (the shares available for public trading). Shares ranged from $5.46 to $7.71 and closed at $7.56, up 20.96% from the pre-market close. In after-hours trading Friday, the stock was at $7.35, down 2.78% from the close, as of 4:53 p.m.

Before the report, the stock had slipped 5.95% over four weeks. It closed at $12.50 on Nov. 6, rose to $13.12 on Nov. 9 and ended Nov. 12 at $12.02, with a period high of $13.94 on Nov. 4.

A revenue miss and a lower outlook

Analysts' estimates for third-quarter revenue varied, and the $23.1 million the company reported was below them. Total revenue fell 1.1% from $23.4 million a year earlier. Analysts had expected full-year revenue of about $100.32 million, well above the new range.

Chief executive Joel Becker said third-quarter revenue was "below our expectations." The shortfall centered on several of the largest accounts, he said, where account-specific problems and changes to the field organization caused more disruption than the company had planned for. He added that scheduled fourth-quarter cases have begun to recover.

Leerink Partners cut its rating to Market Perform from Outperform and set a $7 price target. Wells Fargo moved to Equal Weight from Overweight, and JPMorgan to Neutral from Overweight.

Costs fell while sales slipped

  • Revenue from the RNS System, the company's implanted epilepsy device, was $22.9 million, up 1.4% from a year earlier.
  • The net loss narrowed to $3.3 million from $4.9 million. Adjusted EBITDA was $0.4 million, against a loss of $1.3 million a year earlier.
  • Non-GAAP gross margin was 84.8%, up from 82.8%. Non-GAAP operating expenses fell to $19.2 million from $20.7 million.
  • Cash, short-term investments and restricted cash were $49.5 million on Sept. 30, down from $51.9 million at the end of the prior quarter. Long-term borrowings were $59.2 million.
  • The company said the new guidance represents underlying RNS growth of 10% to 11% for 2026. NeuroPace expects about 15% RNS growth in 2027.

What comes next: FDA filings

  • Around the end of 2026: the company expects to submit an amendment to its premarket approval supplement for idiopathic generalized epilepsy, after an October meeting with the FDA.
  • Remote Care, which would let physicians program the RNS System by telehealth, is under FDA review with a planned 180-day cycle.
  • Early 2027: data collection is expected to finish in AURORA, a study aimed at expanding the indication to adolescents aged 12 to 17, followed by analysis and an FDA submission.

Bottom line

Neuropace lost more than a third of its value in one session on a revenue miss and a lower full-year forecast, and it regained only part of the pre-market drop. Management says the weakness is tied to a handful of large accounts and its field organization, and it expects about 15% RNS growth in 2027.


This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.

This article is for informational purposes only and is not investment advice.

Read the original report